**Figure 1: CONSORT diagram (ITT population for immunologic memory)**

Participants in primary vaccination phase: n=509

Randomised for Immunologic memory study (to have 6 day blood after 12th month Hib-MenC-TT vaccine): n=269

Allocated within Single infant dose MenC-TT Group: n=70

Withdrawn: n=6

Missed visit n=1

All participants in Control Group: n=66

Withdrawn: n=4

Missed visit: n=1

Allocated within Two infant dose MenC-CRM Group: n=66

Withdrawn: n=2

Missed visit: n=3

Allocated within Single infant dose MenC-CRM Group: n=67

Withdrawn: n=3

Missed visit: n=2

Eligible n=61

Eligible n=61

Eligible n=63

Eligible n=62

No serum: n=13

No 12 month serum: n=4

No serum: n=9

No 12 month serum: n=6

No serum: n=11

No 12 month serum: n=4

No serum: n=11

No 12 month serum: n=8

Memory B-cells analysis:

12 months: n=19

12 months +6 days: n=15

Analysed n=48

Analysed n=46

Analysed n=42

Analysed n=45

Memory B-cells analysis:

12 months: n=24

12 months +6 days: n=18

Memory B-cells analysis:

12 months: n=13

12 months +6 days: n=18

Memory B-cells analysis:

12 months: n=20

12 months +6 days: n=21

**Figure 2**: MenC rSBA GMTs (and 95% CI) before, at 6 days and at 28 days after the 12 month visit according to type of MenC priming schedule

\*12 month Visit: at 51-58 weeks of age; 12 month + 6 days Visit: 6 days after Hib-MenC-TT vaccination at 51-58 weeks of age; 13 month Visit: 28-42 days after Hib-MenC-TT vaccination at 51-58 weeks of age

MenC rSBA titre <1:4 is represented by 2 on the y axis; Error bars represent the 95% confidence intervals

**Figure 3: Number of MenC specific IgG memory B-cells before, 6 days and 1 month after Hib-MenC-TT immunisation at 12 months of age according to the type of MenC priming schedule (mean represented by crosses)**



p=0.022 vs Control

p=0.002 vs Control



p=0.0015 vs Control

p=0.02 vs MenC-CRM

p=0.05 vs Two dose MenC-CRM

**Supplementary Figure 1**: MenC rSBA GMTs (and 95% CI) at the 12th month and 12th month and 6 days visit in participants with undetectable pre-boost MenC rSBA titres (**1a**) and with pre-boost MenC rSBA titres ≥4 (**1b**) according to type of MenC priming schedule

**1b**

**1a**

\*12 month Visit: at 51-58 weeks of age; 12 month + 6 days Visit: 6 days after Hib-MenC-TT vaccination at 51-58 weeks of age

MenC rSBA titre <1:4 is represented by 2 on the y axis; Error bars represent 95% confidence intervals

Supplementary **Figure 2:** Number of MenC specific IgG memory B-cells at the 12th month and 12th month and 6 days visit in participants with undetectable pre-boost MenC rSBA titres (2a) and with pre-boost MenC rSBA titres ≥4 (2b) according to type of MenC priming schedule (means represented by crosses)

 ****

*Comparisons of the number of memory B-cells at the 12 month and 12 month + 6 days blood sampling visits for each group as well as between groups were not statistically significantly different*

**2a**





*Comparisons of the number of memory B-cells at the 12 month and 12 month + 6 days blood sampling visits for each group as well as between groups were not statistically significantly different*

**2b**